Form 8-K - Current report:
SEC Accession No. 0001628280-26-053832
Filing Date
2026-08-06
Accepted
2026-08-06 07:12:37
Documents
12
Period of Report
2026-08-06
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K sion-20260806.htm   iXBRL 8-K 26074
2 EX-99.1 sion2q26earningsrelease_fi.htm EX-99.1 71708
  Complete submission text file 0001628280-26-053832.txt   225748

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT sion-20260806.xsd EX-101.SCH 1822
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT sion-20260806_lab.xml EX-101.LAB 22777
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT sion-20260806_pre.xml EX-101.PRE 13073
15 EXTRACTED XBRL INSTANCE DOCUMENT sion-20260806_htm.xml XML 3127
Mailing Address 21 HICKORY DRIVE, SUITE 500 WALTHAM MA 02451
Business Address 21 HICKORY DRIVE, SUITE 500 WALTHAM MA 02451 617-819-2020
Sionna Therapeutics, Inc. (Filer) CIK: 0002036042 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-42504 | Film No.: 261245951
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)